Standard therapy for PV involves phlebotomy and cytoreductive drugs (hydroxyurea, busulfan) but recently IFN-α and JAK1/2 inhibitors have been examined as potential treatments (102, 103). This evidence concerns the gene IFNA2 and acquired polycythemia vera.